Bio-Techne licenses AI-designed proteins from Monod Bio
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Bio-Techne Licenses AI-Designed NovoBody™ Duo Molecules from Monod Bio to Expand Recombinant Protein Portfolio
November 18, 2025 6:30 AM ESTPartnership strengthens Bio-Techne's leadership in AI-enabled protein innovation NovoBody Duo molecules offer multi-specific binding capabilities for advanced research and diagnostics Collaboration aligns with Bio-Techne's strategic growth pillars and megatrends in precision medicine
MINNEAPOLIS and SEATTLE, Nov. 18, 2025 /PRNewswire/ --Â Bio-Techne Corporation (NASDAQ:... More



